Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 99-104

  Corbeau, P ^a,b   Kraus, G ^a,d   Wong Staal, F ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Gene therapy, AIDS; Monocytes; Packaging cell line; Retroviral vector

Indexed keywords

CD4 ANTIGEN; CIS ACTING ELEMENT;

ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MACROPHAGE; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0031974254     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300563     Document Type: Article

References (28)

1. Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV infection (Review). Gene Therapy 1994; 1: 13-26.
2. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996; 93: 14070-14075.
3. Rizvi Ta, Panganiban AT. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol 1993, 67: 2681-2688.
4. Parolin C et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol 1994; 68: 3888-3895.
5. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66: 150-159.
6. Bray M et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994; 91: 1256-1260.
7. Zolotukhin AS et al. Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a ris-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J Virol 1994; 68: 7944-7952.
8. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mote Cell Biol 1986; 6. 2895-2902.
9. Benkirane M et al. An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. EMBO J 1993, 12: 4909-4921.
10. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector (see comments). Science 1996; 272: 263-267.
11. Poeshla E, Corbeau P, Wong-Staal F. Developing HIV-1 vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996; 93: 11395-11399.
12. Zack JA et al. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66: 1717-1725.
13. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994; 91: 6992-6996.
14. Lever A et al. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 1989; 63: 4085-4087.
15. Aldovini A, Young RA. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol 1990, 64: 1920-1926.
16. Clavel F, Orenstein JM. A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. J Virol 1990; 64: 5230-5234.
17. Carroll R et al. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol 1994; 68: 6047-6051.
18. Yu H et al. Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 1996; 70: 4530-4537
19. Lori F et al. Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence. j Virol 1992; 66: 5553-5560.
20. Garzino-Demo A, Gallo RC, Arya SK. Human immunodeficiency virus type 2 (HIV-2): packaging signal and associated negative regulatory element. Hum Gene Ther 1995; 6: 177-184.
21. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991; 349: 167-169.
22. Bukrinsky MI et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of nondividing cells (see comments) Nature 1993; 365: 666-669.
23. Heinzinger NK et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91: 7311-7315
24. Yu M et al. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1995; 92: 699-703.
25. + cells. Exp Hematol 1996; 24: 738-747.
26. Neering SJ et al. Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood 1996; 88: 1147-1155.
27. Talbott R et al. Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity. Proc Natl Acad Sci USA 1993; 90: 4226-4230.
28. Kornbluth RS et al. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med 1989; 169: 1137-1151.